Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

Benzer Materyaller

• Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
  Yazar:: Cohen, Roger B., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?
  Yazar:: Pacheco, Jose M., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
  Yazar:: Piper, Andrew J., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
  Yazar:: Garon, Edward B., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
  Yazar:: Felip, Enriqueta, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)